【摘 要】
:
Neratinib (HIK-272),an irreversible inhibitor of EGFR and Her-2,is in phase Ⅲ clinical trials for patients with Her-2-positive locally advanced or metastat
【机 构】
:
State Key Laboratory of Oncology in South China,Cancer Center,Sun Yat-Sen University,Guangzhou 51006
【出 处】
:
2012医学科学前沿暨第二届个体化治疗与抗肿瘤药物研究新趋向研讨会